CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays ...

BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid out key timelines for upcoming launches and pipeline programs during a ...

BridgeBio Pharma Inc. BBIO on Wednesday announced a recent presentation of interim results from its Phase 3 FORTIFY trial for BBP-418, a treatment for limb-girdle muscular dystrophy type 2I/R9.

BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, ...

BridgeBio Pharma sees its Relative Strength Rating move into the elite 90-plus level.

Barclays 28th Annual Global Healthcare Conference March 11, 2026 12:30 PM EDTCompany ParticipantsNeil Kumar - Co-Founder, ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the 10 Stocks Investors Are Watching. BridgeBio saw its share prices jump by 13 ...

Data from BridgeBio Pharma’s Phase 3 FORTIFY study show that BBP-418 significantly increases levels of a key disease biomarker that helps stabilize muscles in patients with limb-girdle muscular ...

US biotech BridgeBio (Nasdaq: BBIO) reported positive interim Phase III data for BBP-418 in limb-girdle muscular dystrophy, ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...

In a market report, JPMorgan raised its price target for BridgeBio Pharma Inc. (NASDAQ:BBIO) to $94 from $89 previously, marking a 26 percent upside potential from its latest closing price.

BridgeBio Pharma (NASDAQ:BBIO) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...